By Ingrid coninx, Hans Rijnten, Mirjam Mol and James Wilson presented at the 19th TCI Global Conference, Eindhoven, 2016.

1. Titel presentatie
[Naam, organisatienaam]
Working Day - Track: Modern cluster policy
Dutch clusters on stage
Ingrid Coninx, Hans Rijnten, Mirjam Mol & James Wilson
Dutch clusters on stage

2. Dutch Clusters on Stage
Ingrid Coninx, Wageningen Environmental Research
Hans Rijnten, Economic Board Utrecht
Mirjam Mol, Pivot Park
James Wilson, Orkestra – Basque Institute of
Competitiveness

3. Large variety
3

4. TCI GLOBAL CONFERENCE 2016
Dutch clusters on the stage
Hans Rijnten, Economic Board Utrecht
November 10, 2016

5. Megatrend 1: Climate Change

6. Megatrend 2: Ageing population

7. Megatrend 3: Digitalisation

8. Economic Board Utrecht
Economic Research – our strenghts

9. Economic Board Utrecht
Triple helix partners

10. • Societal challenge = economic
opportunity
• Strategic agenda:
o green economy
o Life sciences & health
o Service innovation
• Private commitment (businesses)
• Scalable
• Reinforcement profile region
Economic Board Utrecht
Regional agenda 2013-2020: Green, Healthy and Smart

11. EBU: Results 2015
Initiatief Bijdrage Vorm Omvang Spin off €
NOM; 033-Energy € 1,4 M Cofin. € 5 M € 90 M
Fiware € 0.94 M Cofin. € 2.64 M € 20 M
Dutch Game Garden € 0.750 M Cofin. € 2.25 M € 20 M
DGA - Control conference € 0.15 M Cofin. € 0.95 M € 2 M
‘Groen-gezond-slim’ fund € 1 M lening € 4 M PM.
NOMMIF € 0.55 M Cofin. € 0.675 M € 7,2 M
MIT-regelingen € 1 M Cofin. € 2 M € 6 M
Totaal € 5,8 M variabel € 17,5 M € 145 M

12. www.pivotpark.com
Pivot Park
The ecosystem
Mirjam Mol
10 November 2016

13. ● 13
Pivot Park is a unique park in the Netherlands
THE place for innovative drug
discovery research and development in
the Netherlands: form target to market
Where chemistry and biology meet
Turn key facilities: state of the art
laboratories, offices, completely
furnished and equipped to start
research or development activities
Unique core facilities:
Modern equipment which is needed for
biological, chemical and analytical lab
research
two pilot plants
ultra high throughput screening facility with
compound collection
R & D services (equipment / utilities /
waste management) by a team of
experts; customized solution for our
customers

14. History

15. Analytic
s
HTS
uHTS
Compou
nds
Pilot
Plant
s
Lab &
Office
facilities
• Fully equipped
labs
• Open Access
labs
• Flex labs
• Nuclear
Magnetic
Resonance
• Liquid
Chromatograph
y
• Mass
Spectrometry
• Open Access
HTS
• Flexible uHTS
• Hit / Lead
optimization
• Up to 10 kg
• GMP standard
• Small
Unieke faciliteiten, apparatuur, kennis en
bedrijfsvoering

16. Growth of the Pivot Park Community

17. Pivot Park community (September 2016)
CROs
Product
developm
ent
CMOs
Other
service
s

18. Pivot Park community – R&D pathway
(September 2016)
Acerta Pharma
APO-T
Aduro Biotech Europe
Glycostem
InnatOss
Lead Pharma
Litevax
Modiquest
NTRC
Osteo-Pharma
SynAffix
Productdevelopment
3D-PharmXchange
CRO
AUTHOR!
BioAxis
BioXpert
InProcess-LSP
Pivot Park Screening Centre
Spinnovation Analytical
Quality by Design
Quantitative Solutions
Quintiles
Zwiers Regulatory
CRO
Aspen
CMO
BioConnection
ChemConnection
CMO
Arnold+Siedsma BAMInfra Strukton
Otherservices
Bogaerts en Groenen CVIS Thema groep
Dotcombusiness ESP Van Oss Groep
Friday Life Sciences Hulshof Kroonen & Groen
Ekoy Investment Partners Rescop
Otherservices
RegistrationTarget
discovery
Lead
discovery
Lead
optimization
Pre-clinical
development
Clinical
phase I
Clinical
phase II
Clinical
phase III
Large
scale
manufacturing

19. Pivot Park Community
Benefits of the ecosystem
• Inspiration by interaction
• New opportunities for
collaboration
• Diversity: from target to
market
• Sharing high-end
facilities = cost reduction
• Strong position in
regional, national and
international knowledge
infrastructure

20. Main trend in innovative entrepreneurship worldwide!
Facilitating open innovation
Closed
innovatio
n
Open
innovatio
n
From closed …
• Solo-creation
• Transactions
• IP legal drive
• Academic research
funding by
industry
• Large enterprises
determine market
access for
innovation
… to open
innovation:
• Co-creation
• Networks/Relations
hips
• Entrepreneurial
drive
• Commercial &
Academic research
collaboration
• SMEs accelerate
market access in
innovation

21. Screening consortia
TKI Oncodrugs
Target
ID
HTS
Hit
Optimisation
Lead
Optimisation
Development
Candidate
Clinical
Development
Identification and development of compounds for different targets
• NKI, NTRC, Covalution BioSciences and Lead Pharma  targets
• PPSC  High Throughput Screening using their compound library
• Leids Instituut voor Chemie (LIC)  MedChem (in close collaboration with PPSC)
• NKI  testing
• Lead Pharma, Covalution BioSciences and NTRC  MedChem, H2L and LO
Objective: Find lead series/clinical candidates in the field of oncology and interest
from big pharma
Covalution BioSciences